Geron Corp - GERN STOCK NEWS

Geron Corporation (Nasdaq: GERN) announced presentations at the 62nd American Society of Hematology Annual Meeting, showcasing clinical data on imetelstat, its first-in-class telomerase inhibitor. Findings from the IMerge and IMbark Phase 2 trials evidence imetelstat’s disease-modifying activity and potential clinical benefits, particularly in lower risk myelodysplastic syndromes (MDS) and refractory myelofibrosis (MF). Key results include 42% of MDS patients achieving durable transfusion independence and significant improvements in overall survival among MF patients.

Geron Corporation (Nasdaq: GERN) announced the grant of a non-statutory stock option for 80,000 shares of its common stock to a newly-hired employee. This option was issued on November 18, 2020, at an exercise price of $1.90 per share, matching the closing price on the grant date. The option has a 10-year term and vests over four years, beginning with a 12.5% vesting after six months and the rest in monthly installments. This action complies with Nasdaq Listing Rule 5635(c)(4) and pertains to Geron's 2018 Inducement Award Plan.

Geron Corporation (Nasdaq: GERN) announced that its CEO, John A. Scarlett, will present a company overview at the Stifel Virtual Healthcare Conference on November 17, 2020, at 2:40 p.m. ET. A live audio webcast of the presentation will be accessible on Geron’s website, with an archived version available for 30 days post-event. Geron focuses on developing imetelstat, a first-in-class telomerase inhibitor for hematologic myeloid malignancies. For more details, visit www.geron.com.

Geron Corporation (Nasdaq: GERN) reported a net loss of $19.7 million for Q3 2020, slightly higher than the $15.2 million lost in Q3 2019. Revenue for the third quarter was $108,000, compared to $131,000 for the same period last year. The company continues to advance its imetelstat program, despite COVID-19 related challenges that may delay trial enrollment. Geron has approximately $274 million in cash, expected to support operations until the end of 2022, and plans to begin two Phase 3 trials in early 2021.

Geron Corporation (Nasdaq: GERN) announced that ten abstracts related to imetelstat, its telomerase inhibitor, are accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting scheduled online from December 5-8, 2020. The abstracts highlight data from Phase 2 trials supporting ongoing Phase 3 studies in lower risk myelodysplastic syndromes (MDS) and myelofibrosis (MF). Notably, 42% of patients achieved red blood cell transfusion independence lasting over 20 months. The expected improvements in overall survival may mark significant advances in treating these conditions.

Geron Corporation (Nasdaq: GERN) will release its third quarter 2020 financial results on November 5, 2020, after market close. The results will be discussed in a conference call at 4:30 p.m. ET the same day. The press release will be available on the company’s website. A live webcast of the call will also be accessible, with archived options available for 30 days. Geron is focused on developing its telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies.

Geron Corporation (Nasdaq: GERN) announced the publication of positive data from the IMerge Phase 2 trial of imetelstat in the Journal of Clinical Oncology, highlighting its effectiveness for patients with lower risk myelodysplastic syndromes (MDS). The trial demonstrated a median transfusion independence duration of 21 months without new safety signals. These results support ongoing Phase 3 trials aimed at addressing anemia in MDS patients. The publication indicates increasing interest from the oncology community, enhancing the potential for future regulatory approval.

Geron Corporation (NASDAQ: GERN) announced a loan facility of up to $75 million with Hercules Capital and Silicon Valley Bank to support its development program for imetelstat. The financing provides non-dilutive resources for working capital and advancing two Phase 3 clinical trials: the ongoing IMerge trial for lower risk myelodysplastic syndromes and a planned trial for refractory myelofibrosis. The loan is structured in three tranches, with $25 million disbursed initially, and additional amounts contingent on achieving clinical milestones.

Geron Corporation (Nasdaq: GERN) announced a positive opinion from the EMA for its orphan drug designation of imetelstat for treating myelodysplastic syndromes (MDS). This designation could provide a 10-year marketing exclusivity in the EU post-approval. The ongoing IMerge Phase 3 clinical trial is set to enroll about 170 patients, with completion expected by Q1 2021 and results in H2 2022. Imetelstat has also received orphan drug status from the U.S. FDA. The company anticipates final approval by the European Commission by the end of July 2020.